Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
| Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
|---|---|---|---|---|---|
| IL2-H82E9 | Human | Biotinylated Human IL-1 Rrp2 / IL-1 R6 Protein, His,Avitag™ |  |
|
|
| IL2-H52H4 | Human | Human IL-1 Rrp2 / IL-1 R6 (C154S, C262S) Protein, His Tag (MALS verified) |  |
|
|
| IL2-C52H5 | Cynomolgus | Cynomolgus IL-1 Rrp2 / IL-1 R6 Protein, His Tag |  |
|
|
| IL2-H5254 | Human | Human IL-1 Rrp2 / IL-1 R6 Protein, Fc Tag |  |
|
|
| IL2-H52H6 | Human | Human IL-1 Rrp2 / IL-1 R6 Protein, His Tag |  |
|
Immobilized Anti-IL36R Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Human IL-1 Rrp2 (C154S, C262S) Protein, His Tag (Cat. No. IL2-H52H4) with a linear range of 4-125 ng/mL (QC tested).
The purity of Human IL-1 Rrp2 (C154S, C262S) Protein, His Tag (Cat. No. IL2-H52H4) is more than 90% and the molecular weight of this protein is around 50-65 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Spesolimab | BI-655130 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | 圣利卓, Spevigo | United States | Psoriasis | Boehringer Ingelheim Pharmaceuticals Inc | 2022-09-01 | Netherton Syndrome; Psoriasis; Colitis, Ulcerative; Hidradenitis Suppurativa; Crohn Disease; Dermatitis, Atopic | Details |
| Spesolimab | BI-655130 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | 圣利卓, Spevigo | United States | Psoriasis | Boehringer Ingelheim Pharmaceuticals Inc | 2022-09-01 | Netherton Syndrome; Psoriasis; Colitis, Ulcerative; Hidradenitis Suppurativa; Crohn Disease; Dermatitis, Atopic | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Imsidolimab | ANB-019 | Phase 3 Clinical | Anaptysbio Inc | Acne Vulgaris; Ichthyosis; Psoriasis; Acneiform Eruptions; Hidradenitis Suppurativa | Details |
| HB-0034 | HB-0034 | Phase 2 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Psoriasis | Details |
| IMG-008 | IMG008 | Phase 1 Clinical | Inmagene Biopharmaceuticals Ltd | Autoimmune Diseases; Inflammation | Details |
| Imsidolimab | ANB-019 | Phase 3 Clinical | Anaptysbio Inc | Acne Vulgaris; Ichthyosis; Psoriasis; Acneiform Eruptions; Hidradenitis Suppurativa | Details |
| HB-0034 | HB-0034 | Phase 2 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Psoriasis | Details |
| IMG-008 | IMG008 | Phase 1 Clinical | Inmagene Biopharmaceuticals Ltd | Autoimmune Diseases; Inflammation | Details |
This web search service is supported by Google Inc.
A-Z
